Recent advances in the medicinal chemistry of antisense oligonucieotides

Current Opinion in Drug Discovery and Development

Volumn 3, Issue 2, 2000, Pages 203-213

  Uhlmann, Eugen ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Binding affinity; Phosphorothioate; Rnase h; Sugar modification

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RIBONUCLEASE H;

BINDING AFFINITY; CHEMICAL MODIFICATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RESEARCH; DRUG STABILITY; DRUG STRUCTURE; ENZYME INDUCTION; REVIEW;

EID: 0034002916     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Wahlestedt C, Good L, Antisense oligonucleotides - the way forward. CurrOpin Drug Discovery Dev (\Q99) 2:142-146.
2. Crooke ST, Vitravene - another piece In the mosaic. Antisense Nucleic Acid Drug Dev (1998) 8:vii-viii.
3. Crooke ST, Basic principles of antisense therapeutics. Handbook Exp Pharmacot (1998) 131:1 -50.
4. lyer RP, Roland A, Zhou W, Ghosh K, Modified oligonucleotides - synthesis, properties and applications. Curr Opin Mol Trier (1999) 1:344-358.
5. Verma S, Eckstein F, Modified oligonucleotides: Synthesis and strategy for users. Annu RevBiochem (1998) 67:99-134.
6. Cook PD, Antisense medicinal chemistry. Handbook Exp P/?armaco/(1998) 131:51-101.
7. Engels JW, Uhlmann E, Chemistry of oligonucleotides. In: Pharmaceutical aspects of oligonucleotides. Couvreur P, Malvy C (Eds), Taylor & Francis, London (2000):35-78.
8. Koziolkiewicz M, Krakowiak A, Kwinkowski M, Boczkowska M, Stec WJ, Stereodifferentiation - the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res (1995) 23:5000-5005.
9. Koziolkiewicz M, Wojcik M, Kobylanska A, Karwowski B, Rebowska B, Guga P, Stec WJ, Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: Diastereoselectivity of plasma 3'-exonuclease. Antisense Nucleic Acid Drug Dev (1997) 7:43-48.
10. Gilar M, Beienky A, Budman Y, Smisek DL, Cohen AS, Impact of 3'-exonuclease stereoselectivity on the kinetics of phosphorothioate oligonucleotide metabolism. Antisense Nucleic Acid Drug Dev (1998) 8:35-42.
11. Crooke RM, Graham MJ, Martin MJ, Lemonidis KM, Wyrzykiewiecz T, Cummins LL, Metabolism of antisense oligonucleotides In rat liver homogenstes. J Pharmacol Exp Ther (2000) 292:140-149.
12. van der Laan AC, Havenaar P, Costing RS, Kuyl-Yeheskiely E, Uhlmann E, van Boom JH, Optimization of the binding properties of PNA-(5')-DNA chimerae. Bioorg Med Chem Lett (1998)8:663-668.
13. Bonham MA, Brown S, Boyd AL, Brown PH, Bruckenstein DA, Hanvey JC, Thomson SA, Pipe A, Hassman F, Bisi JE, Froehler BC, Matteucci MD, Wagner RW, Noble SA, Babiss LE, An assessment of the antisense properties of RNase H-competent and steric-blocking oligomers. Nucleic Acids Res (1995) 23:1197-1203.
14. Knudsen H, Nielsen PE, Antisense properties of duplex- and triplex-forming PNAs. Nucleic Acids Res (1996) 24:494-500.
15. Mologni L, Lecoutre P, Nielsen PE, Gambacorti-Passerini C, Additive antisense effects of different PNAs on the in vitro translation of the PML/RARcc gene. Nucleic Acids Res (1998) 26:1934-1938.
16. Dias N, Dheur S, Nielsen PE, Gryaznov S, Van Aerschot A, Herdewijn P, Hélène C, Saison-Behmoaras TE, Antisense PNA tridecamers targeted to the coding region of Ha-ras mRNA arrest polypeptide chain elongation. J Mol Biol (1999)294:403-416.
17. Mologni L, Nielsen PE, Gambacorti-Passerini C, In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. Biochem Biophys Res Commun (1999) 264:537-543.
18. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, Kahl U, Hao J-X, Xu X-J, Wiesenfeld-Hallin Z, Hokfelt T, Bartfai T, Langel U, Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission In vivo. Nature Biotechnol (1998) 16:857-861.
19. Branden LJ, Mohamed AJ, Smith CI, A peptide nucleic acidnuclear localization signal fusion that mediates nuclear transport of DNA. Nature Biotechnol(1999) 17:784-787.
20. Aldrian-Herrada G, Desarmenien MG, Orcel H, Boissin-Agasse L, Mery J, Brugidou J, Rabie A, A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res (1998) 26:4910-4916.
21. Chinnery PF, Taylor RW, Diekert K, till R, Tumbull DM, Lightowlers RN, Peptide nucleic acid delivery to human mitochondria. Gene 77w(1999) 6:1919-1928.
22. Basu S, Wickstrom E, Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug Chem (1997) 8:481-488.
23. Penichet ML, Kang Y-S, Pardridge WM, Mom'son SL, Shin S-U, An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: Initial applications In anti-HIV antisense drug delivery to the brain. J Immunot (1999) 163:4421 -4426.
24. Tyler BM, Jansen K, McCormick DJ, Douglas CL, Boules M, Stewart JA, Zhao L, Lacy B, Cusack B, Fauq A, Richelson E, Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proc Natl Acad Sci USA (1999) 96:7053-7058.
25. Jansen K, Richelson E, Detection of peptide nucleic acids in tissue extracts of treated animals. J Biochem Biophys Methods (2000) 42:31-34.
26. Summerton J, Morpholino antisense oligomers: The case for an RNase H-independent structural type. Biochim Biophys Acta (1999) 1489:141-158.
27. Giles RV, Spiller DG, Clark RE, Tidd DM, Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev (1999) 9:213-220.
28. Schmajuk G, Sierakowska H, Kole R, Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J Biol Chem (1999) 274:21783-21789.
29. Freier SM, Artmann K-H, The ups and downs of nucleic acid duplex stability: Structure-stability studies on chemicallymodified DNAiRNA duplexes. Nucleic Acids Res (1997) 25:4429-4443.
30. Griffey RH, Monia BP, Cummins LL, Freier S, Greig MJ, Guinosso CJ, Lesnik E, Manalili SM, Mohan V, Owens S, Ross BR, Sasmor H, Wancewicz E, Weiler K, Wheeler PD, Cook PD: 2'-O-aminopropyl ribonucleotides: A zwitterionic modification that enhances the exonuclease resistance and biological activity of antisense oligonucleotides. J Med Chem (1996) 39:5100-5109.
31. Manoharan M: -Carbohydrate modifications in antisense oligonucleotide therapy: Importance of conformation, configuration and conjugation. Biochim Biophys Acta (1999) 1489:117-130.
32. Teplova M, Wallace ST, Tereshko V, Minasov G, Symons AM, Cook PD, Manoharan M, Egli M, Structural origins of the exonuclease resistance of a zwitterionic RNA. Proc Natl Acad Sci USA (1999) 96:14240-14245.
33. Herdewijn P, Conformationally restricted carbohydratemodified nucleic acids and antisense technology. Biochim Biophys Acta (1999) 1489:167-179.
34. Koshkin M, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M, Olsen CE, Wengel J, LNA (locked nucleic acids): Synthesis of the adenine, cytosine, guanine, 5methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerization, and unprecedented nucleic acid recognition. Tetrahedron (1998) 54:3607-3630.
35. Rajwanshi VK, Häkansson AE, Kumar R, Wengel J, High affinity nucleic acid recognition using 'LNA' (locked nucleic acid, -D-ribo configured LNA), 'xy/o-LNA' (-Dxylo configured LNA) or 'a-L-LNA1 (a-L-n'bo configured LNA). Chem Comm(1999) 1999:2073-2074.
36. Hendrix C, Rosemeyer H, De Bouvere B, Van Aerschot A, Seela F, Herdewijn P: 1',5'-anhydrohexitol oligonucleotides, Hybridization and strand displacement with oligoribonucleotides, interaction with RNase H and HIV reverse transcriptase. Chem Eur J(1997) 3:1513-1520.
37. Vandermeeren M, Preveral S, Janssens S, Geysen J, SaisonBehmoaras E, Van Aerschot A, Herdewijn P, Biological activity of hexitol nucleic acids targeted at Ha-ras and intracellular adhesion molecule-1 mRNA. Biochem Pharmacol (2000) 59:655-663.
38. Damha MJ, Wilds CJ, Noronha A, Brukner I, Borkow G, Arion D, Parniak MA, Hybrids of RNA and arabinonucleic acids (ANA and 2'F-ANA) are substrates of Ribonuclease H. JAm Chem Soc{1998) 120:12976-12977.
39. Wang J, Herdewijn P, Enantioselective synthesis and conformational study of cyclohexene carbocyclic nucleosides. J Org Chem (1999) 64:7820-7827.
40. Herdewijn P, Conference Report. Frontiers of Nucleic Acid Chemistry. Osnabrueck, Germany (1999).
41. Wagner RW, Matteucci MD, Grant D, Huang T, Froehler BC, Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature Biotechnol (1996) 14:840844.
42. Ojwang JO, Mustain SD, Marshall HB, Rao TS, Chaudhary N, Walker DA, Hogan ME, Akiyama T, Revankar GR, Peyman A, Uhlmann E, Rando RF, Modified antisense oligonucleotides directed against tumor necrosis factor receptor type I inhibit tumor necrosis factor a-mediated functions. Biochemistry (1997) 36:6033-6045.
43. Balow G, Mohan V, Lesnik EA, Johnston JF, Monia BP, Acevedo OL, Biophysical and antisense properties of oligodeoxynucleotides containing 7-propynyl-, 7-iodo- and 7-cyano-7-deaza-2-amino-2'-deoxyadenosines. Nucleic Acids Res (1998) 26:3350-3357.
44. Benimetskaya L, Berton M, Kolbanovsky A, Benimetsky S, Stein CA, Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-KB p65) 'antisense1 oligodeoxynucleotide. Nucleic Acids Res (1997) 25:2648-2656.
45. Sharma HW, Hsiao R, Narayanan R, Telomerase as a potential molecular target to study G-quartet phosphorothloates. Antisense Nucleic Acid Drug Dev (1996) 6:3-7.
46. Flanagan WM, Wagner RW, Grant D, Un K-Y, Matteucci MD, Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide. Nature Biotechnol (1999) 17:48-52.
47. Flanagan WM, Wolf JJ, Oison P, Grant D, Lin K-Y, Wagner RW, Matteucci MD, A cytosine analog that confers enhanced potency to antisense oligonucleotides. Proc Nat! AcadSci USA (1999) 96:3513-3518.
48. Uhlmann E, Peyman A, Will DW, Antisense: Chemical modifications. In: Encyclopedia of Cancer. Bertino JR (Ed), Academic Press, San Diego (1997):64-81.
49. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Guinosso CJ, Komburst D, Manoharan M, Sasmor HM, Schleich T, Tlvel KL, Griffey RH, Pharmacokinetic properties of several novel oligonucleotides analogs in mice. J Pharmacol Exp Ther (1996)277:923-937.
50. Bleczinski CF, Richert C, Steroid-DNA interactions Increasing stability, sequence-selectivity, DNA/RNA discrimination, and hypochromicity of oligonucleotide duplexes. JAm Chem Soc(1999) 121:10889-10894.
51. Rait A, Pirollo K, Will DW, Peyman A, Rait V, Uhlmann E, Chang EH: 3'-end conjugates of minimally phosphorothioate-protected oligonucleotides with 1-Ohexadecylglycerol: Synthesis and anti-ras activity in radiation-resistant cells. Bioconjug Chem (2000) in press.
52. Tosquellas G, Alvarez K, Dell'Aquila C, Morvan F, Vasseur J-J, Imbach J-L, Rayner B, The pro-oligonucleotide approach: Solid phase synthesis and preliminary evaluation of model prododeca-thymidylates. Nucleic Acids Res (1998) 26:2069-2074.
53. Vives E, Dell'Aquila C, Bologna J-C, Morvan F, Rayner B, Imbach J-L, Lipophilic pro-oligonucleotides are rapidly and efficiently internalized in HeLa cells. Nucleic Acids Res (1999) 27:4071-4076.
54. Mauritz RP, Meier C, Uhlmann E, Synthesis of 3',5'dithymidylyl-a-hydroxyphosphonate dimer building blocks for oligonucleotide synthesis - a new pro-oligonucleotide approach. Nucleosides Nucleotides (1997) 16:1209-1212.
55. Mauritz RP, Meier C: Elucidation of the hydrolytical properties of a-hydroxybenzylphosphonates as a new potential pro-oligonucleotide concept Nucleosides Nucleotides (1999) 18:1417-1418.
56. Uhlmann E, Peyman A, Antisense oligonucleotides: A new therapeutic principle. Chem Rey(1990) 90:543-584.
57. Stein CA, Phosphorothloate antisense oligodeoxynucleotides: Questions of specificity. Trends Biotechnol (1996) 14:147-149.
58. Agrawal S, Zhao Q, Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev (1998) 8:135-139.
59. Inoue H, Hayase Y, Iwai S, Ohtsuka E, Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS /_ett(1987) 215:327-330.
60. Crooke ST, Lemonidis KM, Neilson L, Griffey R, Lesnik EA, Monia BP, Kinetic characteristics of Escherichla coli RNase H1: Cleavage of various antisense oligonucleotideRNA duplexes. Biochem J(1995) 312:599-608.
61. Wu H, Lima WF, Crooke ST, Properties of cloned and expressed human RNase H1. J Biol Chem (1999) 274:2827028278.
62. Agrawal S, Importance of nucleotide sequence and chemical modifications of antisense oligonucteotides. Biochim BiophysActa (1999) 1489:53-67.
63. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R, Antitumor activity and pharmacokinetics of a mixedbackbone antisense oligonucleotide targeted to the Riot subunit of protein kinase A after oral administration. Proc NatlAcadSci USA (1999) 96:13989-13994.
64. Peyman A, Uhlmann E, Minimally modified oligonucleotides - combination of end-capping and pyrimidine-protection. Biol Chem Hoppe Seyter(1996) 377:67-70.
65. Uhlmann E, Peyman A, Byte A, Schmidt A, Buddecke E, Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression. Methods Enzymol (2000) 313:268-284.
66. Uhlmann E, Ryte A, Peyman A, Studies on the mechanism of stabilization of partially phpsphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev (1997) 7:345-350.
67. Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB, Baron R: c-Cbl is downstream of c-Src In a signalling pathway necessary for bone résorption. Nature (1996) 383:528-531.
68. Sproat BS, Iribarren A, Beijer B, Pieles U, Lamond AI: 2'-OAlkyloligoribonucleotides: Synthesis and applications in studying RNA splicing. Nucleosides Nucleotides (1991) 10:25-36.
69. Froehler BC, Wadwani S, Terhorst TJ, Gerrard SR, Oligodeoxyribonucleotides containing C-5 propyne analogs of 2'-deoxyuridine and 2'-deoxycytidine. Tetrahedron Lett (1992) 33:5307-5310.
70. Uhlmann E, Homung L, Hein S, Augustin S, Peyman A, Will DW, Helsberg M, Sagi J, Otvos L, Ojwang JO, Mustain S, Rando RF, Enhanced biological activity of antisense oligonucleotides containing 5-{1-hexynyl)-substituted pyrimidine nucleotides. Nucleosides Nucleotides (1997) 16:1717-1720.
71. Hyrup B, Nielsen PE, Peptide nucleic acids (PNA): Synthesis, properties and potential applications. Bioorg Med Chem (1996) 4:5-23.
72. Uhlmann E, Peyman A, Breipohl G, Will DW, PNA: Synthetic polyamide nucleic acids with unusual binding properties. Angew Chem Int Ed Engl (1998) 37:2796-2823.
73. Uhlmann E, Will DW, Sreipohl G, Langner D, Ryte A, Synthesis and properties of PNA/DNA chimeras. Angew Chem Int Ed Engl (1996) 35:2632-2635.
74. Uhlmann E, Peptide nucleic acids (PNA) and PNA-DNA chimeras: From high binding affinity towards biological function. Biol Chem (1998) 379:1045-1052.
75. Cummins L, Graff D, Beaton G, Marshall WS, Caruthers MH, Biochemical and physlcochemical properties of phosphorodithioate DNA. Biochemistry (1996) 35:87348741.
76. Rait VK, Shaw BR, Boranophosphates support the RNase H cleavage of polyribonucleotides. Antisense Nucleic Acid Drug Dev (1999) 9:53-60.
77. Mignet N, Gryaznov SM, Zwitterionlc oligodeoxyribonucleotide N3'-P5' phosphoramidates: Synthesis and properties. Nucleic Acids Res (1998) 26:431438.
78. Ma MYX, Jacob-Samuel B, Dignam JC, Pace U, Goldberg AR, George ST, Nuclease-resistant external guide sequenceInduced cleavage of target RNA by human ribonuclease P. Antisense Nucleic Acid Drug Dev (1998) 8:415-426.
79. Werner M, Rosa E, AI Emran O, Goldberg AR, George ST, Targeted cleavage of RNA molecules by human RNase P using minimized external guide sequences. Antisense Nucleic Acid Drug Dev(\999) 9:81-88.
80. Ma M, Benimetskaya L, Lebedeva I, Dignam J, Takle G, Stein CA, Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences. Nature Biotechnol (2000) 18:58-61.
81. Seliger H, Froehlich A, Montenarh M, Ortigao JFR, Roesch H, Oligonucleotide analogs with terminal 3'-3'- and 5'-5'internucleotidic linkages as antisense inhibitors of viral gene expression. Nucleosides Nucleotides (1991) 10:469477.
82. Wemer M, Rosa E, Nordstrom JL, Goldberg AR, George ST, Short oligonucleotides as external guide sequences for site-specific cleavage of RNA molecules with human RNase P. RNA (1998) 4:847-855.
83. Torrence PF, Maitra RK, Lesiak K, Khamnei S, Zhou A, Silverman RH, Targeting RNA for degradation with a (215')oligoadenylate-antisense chimera. P roc Natl Acad Sci USA (1993) 90:1300-1304.
84. Torrence PF, Xiao W, U G, Khamnei S, Development of 2'-5'oligonucleotides as potential therapeutic agents. Curr Med Chem (1994) 1:176-191.
85. Cramer H, Player MR, Torrence PF, Discrimination between ribonuclease H- and ribonuclease L-mediated RNA degradation by 2'-O-methylated 2-5A-antisense oligonucleotides. Bloorg Med Chem Lett (1999) 9:1049-1054.
86. Verheijen JC, Van der Mare! GA, Van Boom JH, Bayly SF, Player MR, Torrence PF: 2'-5'-oligoadenylate-peptide nucleic acids (2-5A-PNAs) activate RNase L. Bioorg Med Chem (1999) 7:449-455.
87. Wu H, MacLeod AR, Lima WF, Crooke ST, Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligorîbonucleotide antisense drugs. JBiol Chem (1998) 273:2532-2542.
88. Gryaznov SM, Oligonucleotide N3'-P5' phosphoramidates as potential therapeutic agents. Biochim Biophys Acta (1999) 1489:131-140.
89. Taylor JK, Dean NM, Regulation of pre-mRNA splicing by antisense oligonucleotides. Curr Opin Drug Discovery Dev (1999)2:147-151.
90. Friedman KJ, Kole J, Cohn JA, Knowles MR, Silverman LM, Kole R, Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFT/7) gene by antisense oligonucleotides. J Biol Chem (1999) 274:36193-36199.
91. Taylor JK, Zhang QQ, Wyatt JR, Dean NM, Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nature Biotechnol (1999)17:1097-1100.
92. Stein CA: Does antisense exist? Nature Med (1995) 1:11191121.
93. Myers KJ, Dean NM, Sensible use of antisense: How to use oligonucleotides as research tool. Trends Pharmacol Sci (2000)21:19-23.